Is it Working? Imaging the Immune Response in Melanoma
14 March 2019
Traditional imaging – such as MRIs or CAT scans – provide insight into the effectiveness of immunotherapy by measuring tumor size. While this works, some patients may take months to respond to immunotherapy and in other cases, tumors may appear to actually grow on these scans, falsely indicating progression.
How Jaqueline’s Promise and Persistence Paid Off
5 March 2019 In Melanoma Stories
Melanoma wasn't supposed to happen to Jacqueline. Melanoma was supposed to be a disease that older, white women got, not 21-year-old African Americans. "People often think having more melanin makes them from developing melanoma. But they’re wrong,” Jacqueline says.
Fight Back Give Back with Clinical Trials
When patients understand all of their options, including clinical trials, they can make informed decisions about their care. For many patients, clinical trials represent the best possible way to get access to cutting-edge treatment options.
Overcoming Targeted Therapy Resistance
Targeted therapies work well for many patients, but most will go on to develop acquired resistance. Researchers are working to address this challenge. Learn about two promising examples.
It’s Not that Simple: Young Women and Melanoma
Article after article describes the ‘skyrocketing’ increases in melanoma among young women. While most are quick to point out the clear association between intentional tanning and skin cancer, few ever hint that there may be more to the story.
UV4Me Reaches Young Adults About Sun Safety
Among young people, rates of melanoma are especially alarming. It is now the second most-common cancer among young women aged 20 – 29. While many programs focus specifically on children, studies suggest that we receive over half of our lifetime exposure to UV after the age of 20. Yet, few evidence-based programs focus specifically on the needs of young adults.
Unchartered Territory: When Should Patients Stop Immunotherapy?
For melanoma patients, deciding when to discontinue treatment is a difficult decision. should the general ‘rule of thumb’ of treating patients with advanced disease until progression still apply? In the absence of definitive data – what does indirect data tell us?
Melanoma Treatment Advances – 2018 in Review
2018 brought new and expanded drug approvals that give patients, doctors, and their families more treatment options with fewer side effects. Learn more about important melanoma treatment advances in 2018.
From Health Scare to Transformative Change
Debra Black founded the Melanoma Research Alliance in 2007 after her own diagnosis with Stage II disease earlier that year. Since then, MRA has become the largest, non-profit funder of melanoma research worldwide.